EP0563091A1 - Impfstoffe auf basis hepatitis-b-oberflächenantigen - Google Patents

Impfstoffe auf basis hepatitis-b-oberflächenantigen

Info

Publication number
EP0563091A1
EP0563091A1 EP92900495A EP92900495A EP0563091A1 EP 0563091 A1 EP0563091 A1 EP 0563091A1 EP 92900495 A EP92900495 A EP 92900495A EP 92900495 A EP92900495 A EP 92900495A EP 0563091 A1 EP0563091 A1 EP 0563091A1
Authority
EP
European Patent Office
Prior art keywords
protein
polypeptide
hbsag
hybrid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92900495A
Other languages
English (en)
French (fr)
Inventor
Frans Van Wijnendale
Michelle Baijot
Jean-Paul Prieels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0563091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909027623A external-priority patent/GB9027623D0/en
Priority claimed from GB919105993A external-priority patent/GB9105993D0/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of EP0563091A1 publication Critical patent/EP0563091A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to improved immunogens which comprise an antigenic polypeptide chemically conjugated to 5 hepatitis B surface antigen (HBsAg) .
  • the invention further relates to novel vaccines and their use .
  • Proteins or synthetic peptides comprising epitopes of different viruses represent potential immunogens for use in 10 vaccines against the infectious diseases caused by the respective viruses.
  • polypeptides frequently require a combination of carriers and adjuvants to become sufficiently immunogenic for consideration as vaccines.
  • Immunogenicity of the hybrid particles was found to be superior to that of an equivalent monomeric CS antigen (Rutgers et aJL., Biotechnology, 1988, .6, 1065) .
  • Vaccines prepared from hybrid immunogenic particles comprising HBsAg protein are also described in European Patent Application Publication No. 0 278 940. In all cases the hybrid particles were obtained by gene fusion rather than chemical coupling techniques.
  • HBsAg protein or a suitable fragment thereof having at least one free sulphydryl group on its surface with another antigen.
  • the present invention provides an immunogenic hybrid polypeptide comprising a first polypeptide component which is HBsAg or fragment thereof displaying the antigenicity of HBV surface antigen, covalently linked via a native sulphur atom in the first polypeptide component to a second polypeptide component.
  • An advantage of the invention is that an antigen may be coupled to the HBsAg particle with cross-linking agents without impairing the immunogenicity of the HBsAg or fragment thereof as defined hereinabove. Furthermore it is possible by the present invention to conjugate the second polypeptide antigen with a vector (the HBsAg particle) which is able to direct its processing via a non-endosomial route. In this way the second antigen can become associated with MHC I antigens and be recognised as such by cytotoxic lymphocytes. Finally chemical coupling allows a higher degree of freedom with regard to antigen (epitope) density on the HBsAg particle and also the possibility of using non-immunogenic spacers whereby the distance from the attachment point to the particle can be varied at will.
  • hybrid polypeptide of the invention may be represented by formula (I) :
  • group P 1 x -S- is HBsAg or fragment thereof displaying the antigenicity of HBV surface antigen bonded via a native sulphur atom;
  • P 2 is a second antigenic polypeptide
  • X is either:
  • P _? comprises a cysteine residue and a hydrophobic anchor group:
  • P2 is selected from gD2 from HSV or is a peptide capable of binding to HIV neutralising antibodies and corresponds to the neutralising domain of the V loop from gpl20; and
  • V3 loop peptides utilised in the present invention are preferably between 10 to 21 amino acids in length and comprises a ⁇ turn flanked by at least one and preferably at least two amino acid on both sides of the ⁇ turn sequences.
  • the sequence corresponds to the sequence 310 to 328 of the gpl ⁇ O protein.
  • the C-terminal tyrosine is optional, as its primary function is to allow labelling with radioactive Iodine.
  • hybrid particles according to the present invention are their ability to induce cellular immunity mediated by T lymphocytes and in particular the ability to induce cytotoxic T lymphocytes (CTL) responses.
  • CTL cytotoxic T lymphocytes
  • P 1 not normally be bonded to P 1 solely through one sulphur atom.
  • P is preferably in particulate form as described below.
  • the HBsAg or fragment thereof used as the first polypeptide component has at least one free thiol on its surface (e.g. may be represented as P ⁇ -SH) and to this end it is important that the HBsAg or fragment thereof is obtained in the correct manner.
  • Hepatitis B virus surface antigen (HBsAg) either in native or recombinant form.
  • the authentic Hepatitis B virus surface antigen can be recovered from plasma of infected individuals as a particle of about 22nm comprised of two proteins known as P24 and its glycosylated derivative GP28, both of which are encoded by the 226 amino acid coding sequence on the HBV genome known as the S-protein coding sequence or HBV S-gene; see Tiollais et al, Nature, 317 (1985), page 489 and references therein.
  • the complete amino acid sequence of, and nucleotide sequence encoding, HBsAg is given in Valenzuela et. a , Nature, 280 (1979), page 815.
  • the numbering system used by Tiollais et. aJL. (loc cit.) to define nucleotide and amino acid positions is used herein.
  • HBV S-gene coding sequences under the control of yeast promoters on expression vectors to enable expression of HBsAg in J3.
  • cerevisiae for vaccine production has been described by, for example, Harford et al in Develop. Biol. Standard. 54: page 125 (1983), Valenzuela et . al.. Nature 298, page 347 (1982) and Bitter et al., J. Med. Virol. 25, page 123 (1988) .
  • Expression in Pichia pastoris has also been described by Gregg et. aJL, Biotechnology, 5_ (1987) , page 479 (see also European Patent Application Publication No. 0 226 846) as has expression in Hansenula polvmorpha (see EP-A- 0 299 108) .
  • HBsAg suitable for use in the present invention since recombinant HBsAg produced in mammalian cells or yeast by the method of Valenzuala and others does not have available free SH groups; it is believed that the cysteine residues of HBsAg are all involved in the formation of disulphide bonds (Wa pler et. al. (Proc.Natl. Acid. Sci. U.S.A. 1985, .82..- 6830-6834 and references therein) .
  • EP-A-0 135435 (assigned to Merck and Co.) describes a method for efficiently converting the non-disulphide bonded HBsAg antigen into a fully intermolecular disulphide bonded particle, alleged to be ten times more immunogenic than the antigen which has not been so treated.
  • HBsAg as produced in S. cerevisiae by SmithKline Beecham Biologicals for the preparation of the vaccine Engerix-B* (Harford et. a_l. loc.cit.) does have an average of four free cysteines per S monomer and does from particles and this has been found to be at least as immunogenic as the fully intermolecular disulphide bonded particle. It will be apparent that when HBsAg is in this form then free cysteines provide one or more native sulphur atoms which can be utilised for coupling the second polypeptide. It will also be appreciated that preferably the HBsAg forms a particle, typically a lipoprotein particle.
  • the first polypeptide component in the hybrid according to the present invention may comprise all or part or parts of the HBsAg precursor protein encoded by the coding sequence which immediately precedes the HBV-S gene on the HBV genome referred to herein as the Pre-S coding sequence.
  • the pre-S coding sequence normally codes for 163 amino acids (in the case the ay HBV sub type) and comprises a pre-SI coding sequence and a Pre-S2 coding sequence. The latter codes for 55 amino acids and immediately precedes the S-protein coding sequence (see EP-A-0 278 940 for further details) .
  • the first polypeptide component P 1 is the HBsAg S-protein having one or more, preferably up to 4, sulfhydryl groups on its surface.
  • the first polypeptide component is preferably prepared by recombinant
  • DNA techniques for example by expression in S. cerevisiae as described by Harford et. a_l (loc.cit.) . i.e. corresponds to or comprises the HBsAg antigen present in the commercial vaccine Engerix-B*.
  • the first polypeptide component may comprise a fragment or truncate of the HBsAg S-protein provided the said fragment has at least one free sulphydryl group on its surface available for coupling to the group X, and provided that particle assembly is not adversely affected.
  • the first polypeptide component may be part of a composite particle comprising at least two polypeptides corresponding to part or all of a protein having the biological activity of one of the hepatitis B surface antigens wherein the particle presents at least two antigenic determinants provided by the S-protein, pre-S2-protein or pre-Sl-protein, said particle optionally containing host specific lipids, as described in copending European Patent Application No. 0414 374.
  • L is the large protein of HBsAg (including the pre-Sl, pre-S2 and S coding sequences as hereinabove defined) and S is the HBsAg S-protein.
  • the first polypeptide component may be a modified L protein of HBsAg as described in copending European Patent Application No. 0414 374 wherein the modified L protein comprises a modified hepatitis B virus large surface protein comprising an amino acid sequence
  • Engerix-B is a Trade Mark encoding the L protein characterized by a modification in at least one of the following sequences: a sequence sensitive to protease digestion, a sequence necessary for myristylation, a sequence necessary for N-linked glycosylation, a sequence necessary for O-linked glycosylation, and a sequence necessary for binding of human serum albumin.
  • the modified L protein may be represented by L* wherein L* has an amino acid sequence comprising residues 12-52 followed by residues 133-145 followed by residues 175-400 of the L protein.
  • first polypeptide in the compound of the present invention may be part of a composite particle (L*,S) wherein L* and S are as hereinabove defined.
  • composite particles may be prepared as described in copending European Patent Application No. 0414 374.
  • the second polypeptide is an antigen useful in the preparation of a polyvalent vaccine and may be of any suitable structure.
  • Specific antigens for P include the recombinant DNA envelope protein gD of Herpes Simplex Virus (HSV) , particularly the truncated form of gD known as gD2t from HSV2.
  • HSV Herpes Simplex Virus
  • Other antigens which may be mentioned are malaria antigens, particularly those derived from the circumsporozoite protein, or antigens derived from HIV envelope protein.
  • the human immunodeficency virus has been identified as the causative pathogen of acquired immunodeficency syndrome (AIDS) .
  • AIDS acquired immunodeficency syndrome
  • Engerix-B is a Trade Mark are definded within the genome by env (viral envelope glycoprotein) and gag (core proteins)genes.
  • the envelope glycoprotein is known as gpl20. After infection with the AIDS virus, human beings develop antibodies against this glycoprotein. In many patients neutralising antibodies are produced although, it is also known that different HIV isolates exhibit a diverse array of sequence variation, particularly in the envelope gene.
  • Peptides from the major neutralising domain located in the envelope protein gpl20 in a region known as the V loop are known to bind to neutralising antibodies generated .in vivo. Nonetheless in order for those peptides to generate neutralising antibodies, correct presentation of the peptide is required.
  • the present invention achieves this, by presenting such peptides on the surface of HBsAg in the manner described herein.
  • the second polypeptide may comprise a hydrophobic anchor group (a hydrophobic 'foot') which may be naturally or synthetically attached to its amino terminal.
  • Suitable hydrophobic anchor groups include fatty acid residues such as myristoyl, palmitoyl and lauryl.
  • hydrophobic anchor group in the second polypeptide component is that it can, via hydrophobic interaction, become embedded in the lipidic membrane associated with the first polypeptide component.
  • the thiol group of the said cysteine can then, by spontaneous oxidation, form an intermolecular disulphide bond with a native thiol group in the first polypeptide component, thereby contributing to the stability of the formed complex.
  • a chemical cross linking agent to form the hybrid according to the invention (i.e. the group X as hereinabove defined may represent a sulphur atom which is native to P 2 as hereinabove defined) .
  • the linker group A as hereinabove defined represents a linear spacer group bonded at one end to a native sulphur atom of the first polypeptide and at the other end to the second polypeptide P via an ammo acid containing side chain in P .
  • Examples of the group A are substituted C2-C- Q alkanes or linear polymers such as polyethylene glycol.
  • Particular groups A include:
  • the present invention further provides a process for the preparation of a hybrid polypeptide of formula (I) :
  • Y is a group capable of reacting with a native thiol group in the first polypeptide;
  • B is a group which is specific for one or more amino acid side chains on the second polypeptide P and A is as hereinabove defined;
  • Heterobifunctional reagents of formula (II) are known in the art and include N-succinimidyl 3- (2-pyridylthio)propionate [SPDP; (III)], succinimidyl 6-maleimidyl hexanoate [EMCS (IV)], and N-succinimidyl 4- (iodoacetyl) amino benzoate [SIAB (V) ] .
  • the ratio of the second polypeptide to the first polypeptide will be in the range 0.1 to 1.0 molecules per monomer. Although in the case of V ⁇ peptides this may be in the range of 1.0 to 4 molecules per monomer.
  • the polypeptide P 1 may be mixed with a mixture of V3 peptides. The resulting fusion with then have different V3 peptide attached to the surface of P .
  • the efficiency of the reaction is such that approximately forty peptides are linked to each particle it being understood that the hybrids according to the invention are preferably in particulate form.
  • the invention provides a vaccine composition comprising an immunoprotective amount of a hybrid polypeptide according to the invention together with a conventional carrier or adjuvant.
  • a preferred adjuvant is de - 3 - 0 - acylated monophosphorylated lipid A (3D-MPL) in a suitable carrier.
  • This adjuvant system provides high neutralising antibody titres.
  • 3D-MPL may be obtained by the methods described in U.K. patent No. 2,211502 (RIBI) .
  • the present inventors have found that exceptional results may be achieved by first adsorbing the HBsAg-V ⁇ peptide conjugate of the present invention on to alum and then admixing with 3D-MPL. Additionally, oil in water emulsions containing 3D-MPL provide excellent results.
  • the oil in water emulsion formulation provided by the present invention most preferably comprises, 3D-MPL, squalane, pluronic L -121 and phosphate buffered saline.
  • the emulsion is preferably passed through a microfluidizer to provide submicron particles in the emulsion. This enhances the activity of the formulation.
  • vaccines containing the hybrid polypeptide according to the invention are prepared by conventional techniques and will contain an immunoprotective amount of the hybrid preferably in buffered physiological saline and admixed or adsorbed with any of the various known adjuvants including aluminium hydroxide and aluminium phosphate.
  • ''immunoprotective'' is meant that enough of the hybrid is administered to elicit a sufficient protective antibody or cell mediated immune response to confer protection against an infectious agent without serious side effects.
  • the amount of hybrid to be administered will depend on whether the vaccine is adjuvanted and will generally comprise between 1 to 1000 meg of total protein, for example 1 to 200 meg total protein, more preferably 5 to 40 meg total protein.
  • the amount and number of doses to be administered can be determined in standard dose range studies involving observation of antibody titres and other responses in subjects.
  • the hybrid polypeptide according to the invention may also be mixed with other antigens such as composite HBsAg particles containing all or part or parts of the PreSl or PreS2 polypeptides for vaccine formulation. It may also be mixed with fused or other chemically synthesised hybrid HBsAg particles carrying epitopes from proteins from other organisms and with other immunogens to form multivalent vaccines.
  • Vaccine preparation is generally described in ''Vaccines'', edited by Voller et at. University Park Press, Baltimore, MD, U.S.A., 1978.
  • the invention provides a method of immunising a subject against viral infection which comprises administering to a subject in need of such immunisation an effective amount of a vaccine composition according to the invention.
  • a method for identifying cysteine-containing peptides in proteins was applied using 2-bromoacetamido-4-nitrophenol (BNP) to introduce an easily detectable probe.
  • BNP 2-bromoacetamido-4-nitrophenol
  • the formation of a covalent bond between the protein sulfhydryl group and the acetamido moiety of BNP introduces a chromophore with an absorbance maximum at 410 mm.
  • the modified protein can then be cleaved with appropriate proteases and the resulting peptides separated by chromatographic methods.
  • Monitoring the effluent at a single wavelength (405 nm) provides a rapid and simple method for detecting and isolating only those peptides which contain cysteine residue(s).
  • HBsAg was from SmithKline Biologicals.
  • NH4HCO3, 2-bromoacetamido-4-nitrophenol (BNP) and chymotrypsin were from Sigma.
  • Trifluoroacetic acid (TFA) and acetonitrile were from Baker (HPLC grade) .
  • N,N-dimethylformamide (DMF) was from Janssen Pharmaceutica.
  • HPLC separation of the peptides was accomplished on a Waters 600 HPLC system fitted with a 250 mm x 4.6 mm Vydac C 4 reverse-phase column. The column was equilibrated with HPLC buffer (NH 4 HC0 3 100 mM, pH 8.5) prior to injection of the sample ( ⁇ 1 mg) . Peptides were eluted with a linear acetonitrile gradient from 0 to 50% in 50 minutes. The elution was monitored at 405 nm and at 224 nm on a Waters 490 Multiwave Detector. Seguence analysis of the BNP peptides
  • Dried sample was redissolved in 60 ⁇ l TFA 6%, and applied on the glass fiber membrane of the sequenator.
  • the membrane was preferably treated with Biobrene.
  • Edman automatic sequential degradation was performed with a liquid phase sequenator (Applied Biosystem 477A) coupled with an amino acid analyser (Applied Biosystem 120A) .
  • HBsAg was from SmithKline Biologicals.
  • Dithiothreitol (DTT) and 2,2'-dithiodipyridine (PDS) were from Serva.
  • PD 10 gel filtration columns were from Pharmacia.
  • Protein ( ⁇ 750 ⁇ g/ml) was dialyzed against buffer (Ure ⁇ . 8M, EDTA 2 mM, 0.1 M Tris-HCl, pH 8.5). PDS (25 M in excess, dissolved in ethanol) was added to the denatured protein. After one hour of incubation at room temperature, excess of PDS was removed by gel filtration (PD 10 column) . Absorbance of the modified protein was measured at 280 nm. Addition of DTT (10 mM final concentration) was made to measure the absorbance of the free thiones at 343 nm.
  • Iodoacetamide was from Merck.
  • HBsAg was used from SmithKline Biologicals.
  • Protein (1 mg/ml) was dialyzed against buffer (Tris 100 mM, EDTA 2mM, pH 8.0) with or without Urea 8M.
  • the S-carboxymethylation of the thiol groups was performed by addition of iodoacetamide (100 moles per mole of sulfhydryl groups) for 20 minutes, in the dark at room temperature.
  • citrate buffer 0.2 N pH 4.25 at 56°C
  • Amino acid detection was made by post-column reaction with ninhydrin and by colorimetrie measurement at 440 and 570 nm.
  • optical densities at 440 and 570 nm are added together and chromatographic data integration were performed on a Shi adzu CR-A3 integrator.
  • peptides containing the BNP label were separated by RPLC and identified by sequencing, following the procedure of Gardner et al. Anal. Biochem., 1987, .672, 140-144.
  • Cysteines in HBsAg particles were carboxymethylated with or without denaturing agent (Urea 8M) .
  • glycoprotein D of HSV 2 (gU2t) expressed in CHO cells (Lasky and Dowbenko DNA, 1984, 3.(1), 23-29) is covalently coupled to a recombinant HBsAg particle containing free SH groups.
  • TNBS 6-Trinitrobenzenesulfonic acid
  • Recombinant gD2t was expressed in CHO cells and purified by SmithKline Biologieals.
  • gD2t was iodinated by the enzymobeads method of PIERCE.
  • HBsAg particles were produced by SmithKline Biologieals.
  • 50 ⁇ l of TNBS/H 2 0 24.5 mM are added to 50 ⁇ l of gD 2 t (58 ⁇ M in Na 2 HP0 4 0.02 M pH 7) diluted in 200 ⁇ l of borate buffer (0.05 M Na 2 B 4 0 7 adjusted to pH 9.5 with 0.05 M NaOH) .
  • gD 2 t (100 ⁇ l) , concentrated (1 mg/ml) and SIAB-activated, is incubated with 53 ⁇ l of HBsAg particles (1 mg/ml in Na 2 HP0 4 10 mM pH 7.2, NaCl 150 mM) for various times at 37C°C.
  • the initial molar ratio gD2/S monomer is 1/1.
  • the particulate gD 2 is purified by a 1.5 M CsCl gradient (45 hours, 65000 rpm in a 70.1 Ti rotor) .
  • 50 ⁇ l of water are added to a vial of enzymobeads. After one hour, 50 ⁇ l of Na 2 HP0 4 0.2 M pH 7.2, 25 ⁇ l gD 2 t (1 mg/ml), 0.5 mCi Nal 125 (Amersham) and 25 ⁇ l 1% ⁇ -D-Glucose are added.
  • the specific activity of the gD2t involved in the coupling may be determined by the radioactivity detected in the mixture of labelled and non-labelled gD t.
  • the amount of gU2t coupled to particles may be determined by this specific activity.
  • gD 2 t is an ideal molecule for the activation step with a heterobifunctional cross-linker without risk of homopolymerisation.
  • the number of free amino groups are detected by TNBS either on the native or on the SIAB activated gD2t.
  • the number of free lysines decreases as a function of the excess of SIAB.
  • the number of detected lysines on the native protein (10) is close to the number determined in the amino acid sequence (11) .
  • the homopolymers elute in the void volume (8 min) and the monomeric gD2t has a retention time of 15 min.
  • formation of homopolymers is observed when gD2t is activated at a concentration of 2.5 mg/ml.
  • An aspecific reactivity of the halogen in SIAB for lysine, methionine or histidine residues may explain this phenomenon (see Means and Feeney, Chemical Modifications of Proteins; Holden Day publ., 1971, page 107) .
  • the HBsAg-gD 2 t conjugate obtained after a 30 min, 2 hrs or over night incubation at 37°C is purified by CsCl gradient.
  • the gP2 homopolymers have a different density to the carrier and do not contaminate the conjugate.
  • the yield of coupling increases with time as shown in Table 2.
  • 0.2 gP2 molecules are coupled per S monomer (twenty per particle) as calculated by radioactivity detected in the particle's density area.
  • Quantitation of the HBsAg-LCF6 hybrid is performed by a 15 sandwich ELISA test using as coating antibody a polyclonal IgG against HBsAg at a concentration of 5 ⁇ l/ml and as detecting antibody a biotinylated monoclonal IgM directed against the repeat sequence of LCF6.
  • Malaria-HBsAg particle Malaria-HBsAg particle of known concentration is used as standard.
  • This ELISA presents the advantage of monitoring the hybrid without prior separation of the free peptides. The results are expressed in ⁇ g/ml equivalent R1 HBsAg. 5
  • the incorporation of the peptide without cysteine and of the peptide without the lauroyl group is compared.
  • the ELISA shows that the lipopeptide lacking cysteine (LF6) fails to incorporate into the HBsAg particle.
  • the peptide without the lauroyl group 5 (CF6) is nearly ineffective. Therefore the synergy between hydrophobic and covalent interactions is critical for the peptide's incorporation into HBsAg particle.
  • the lipopeptide is incubated with classical HBsAg particle ( ⁇ 4 free SH groups/S monomer) , with more oxidized particles (1 free SH group/S monomer) , or with totally oxidized 10 particles (no free SH group; particles synthesized in CHO cells) .
  • the peptide used represents the sequence from amino acid 310 to 328 (G. Larosa, Science 1990, 249-932) comprised in a disulfide bridged loop in the third variable region of the 35 external protein g ⁇ l20. Its conservation is over 80% in 9 out of 14 positions in the central portion and its predicted structural motif is of the type ⁇ strand-type II ⁇ turn- ⁇ strand- ⁇ helix.
  • the primary structure of the peptide can be represented by the following
  • the peptide is synthesized according to the Merrifield solid phase method, giving, after purification by reverse phase 15 hplc, a peptide of 97% purity.
  • the peptide is homogeneous by SDS-PAGE and gel filtration on TSK 2000 column. Its molecular weight is 2800.
  • the V peptide contains one Lysine group which was activated 0 with EMCS for 30 min at 37°C, pH 7, in a 1:1 to 4:1 ratio.
  • the conjugate obtained is purified from the unconjugated 5 peptide by gel filtration on HR 200 column.
  • the coupling 10 efficiency was of 0.4 peptide coupled per HBs monomer, which is equivalent to 40 V 3 peptides per HBs particle or to 1 mg V 3 per 25 mg HBsAg.
  • the vehicle is prepared as follows. To phosphate-buffered saline (PBS) containing 0.4% (v/v) Tween 80 is added 5% (v/v) Pluronic L121 and 10% squalane. This mixture is then microfluidized. For microfluidization, the emulsion is
  • V 3 HBsAg is mixed with an equal volume of twice concentrated V 3 HBsAg and vortex briefly to ensure complete mixing of the components.
  • the final preparation consists of 0.2% Tween 80, 2.5% Pluronic L121, 5% squalane, 50 ⁇ g 3D-MPL and 1 ⁇ g equivalent V 3 peptide (corresponding to 25 ⁇ g HBsAg) in a
  • 1 ⁇ g equivalent V 3 is adsorbed overnight at 4°C on alum corresponding to 0.5 mg equivalents A1 J m 0.25 ml of 150 mM NaCl, 10 mM phosphate buffer pH 6.8. After overnight incubation, the adjuvant preparation is centrifuged and its supernatant removed. An equal volume of adsorption buffer containing 50 ⁇ g 3D-MPL is then added to the alum-bound HBsAg - V 3 peptide.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP92900495A 1990-12-20 1991-12-16 Impfstoffe auf basis hepatitis-b-oberflächenantigen Withdrawn EP0563091A1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909027623A GB9027623D0 (en) 1990-12-20 1990-12-20 Novel compounds
GB9027623 1990-12-20
GB9105993 1991-03-21
GB919105993A GB9105993D0 (en) 1991-03-21 1991-03-21 Vaccines

Publications (1)

Publication Number Publication Date
EP0563091A1 true EP0563091A1 (de) 1993-10-06

Family

ID=26298142

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92900495A Withdrawn EP0563091A1 (de) 1990-12-20 1991-12-16 Impfstoffe auf basis hepatitis-b-oberflächenantigen

Country Status (4)

Country Link
EP (1) EP0563091A1 (de)
JP (1) JPH06503821A (de)
AU (1) AU9052091A (de)
WO (1) WO1992011291A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
PT835663E (pt) * 1992-05-23 2010-01-04 Glaxosmithkline Biolog Sa Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios
IT1256575B (it) * 1992-12-10 1995-12-11 Cesalpino Andrea Fond Procedimento per la preparazione di immunogeni costituiti da antigeni esogeni capaci di generare non solo la risposta immune dei linfociti t helper,ma anche una efficace risposta dei linfociti t citotossici; e immunogeni cosi' ottenibili.
AU6141094A (en) * 1993-02-19 1994-09-14 Smithkline Beecham Biologicals (Sa) Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
EP1175912A1 (de) * 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA 3-0-deazylierte Monophosphoryl Lipid A enthaltende Impfstoff-Zusammensetzungen
KR970061917A (ko) * 1996-02-29 1997-09-12 성재갑 헤르페스 심플렉스 바이러스 당단백질의 항원 결정부위와 b형 간염 바이러스의 표면 항원 단백질의 융합단백질
CA2324289C (en) * 1998-03-09 2010-07-13 Smithkline Beecham Biologicals S.A. Combined vaccine compositions
BR9915771A (pt) 1998-11-30 2001-12-26 Cytos Biotechnology Ag Apresentação molecular ordenada de antìgenos,processo de preparação e utilização
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
JP4516748B2 (ja) 2001-09-14 2010-08-04 サイトス バイオテクノロジー アーゲー ウィルス様粒子中への免疫賦活物質のパッケージ化：調製法および使用法
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
EP1532167B1 (de) 2002-07-17 2012-01-25 Cytos Biotechnology AG Molekulare antigen-anordnung durch verwendung eines virus-ähnlichen partikels vom virus ap205
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
SI1524994T1 (sl) 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US7767212B2 (en) 2005-03-18 2010-08-03 Cytos Biotechnology Ag CAT allergen conjugates and uses thereof
EP1736538A1 (de) 2005-06-21 2006-12-27 Cytos Biotechnology AG Prozess für die preparative Reinigung von Virus-ähnlichen Partikeln (VLPs)
KR20080047564A (ko) 2005-09-28 2008-05-29 사이토스 바이오테크놀로지 아게 인터루킨-1 컨쥬게이트 및 그의 용도
US20070184068A1 (en) 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
NZ573622A (en) 2006-06-12 2011-12-22 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
PE20142330A1 (es) 2008-12-09 2015-01-14 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
WO2011013034A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
CN104548089B (zh) 2009-09-03 2017-09-26 辉瑞疫苗有限责任公司 Pcsk9疫苗
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2680883B1 (de) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9-impfstoff
JP2015527296A (ja) 2012-03-26 2015-09-17 アメリカ合衆国 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達
BR112016013804A2 (pt) 2013-12-16 2017-10-10 Us Health imunoterapia de câncer distribuindo antígenos mhc de classe ii usando um replicon de vlp
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
CN115279905A (zh) 2019-10-23 2022-11-01 里珍纳龙药品有限公司 合成rig-i样受体激动剂
WO2021250628A1 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Bacterial immunization using nanoparticle vaccine
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
GB8903313D0 (en) * 1989-02-14 1989-04-05 Wellcome Found Conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9211291A1 *

Also Published As

Publication number Publication date
JPH06503821A (ja) 1994-04-28
AU9052091A (en) 1992-07-22
WO1992011291A1 (en) 1992-07-09

Similar Documents

Publication Publication Date Title
EP0563091A1 (de) Impfstoffe auf basis hepatitis-b-oberflächenantigen
CA1329766C (en) T cell epitopes of the hepatitis b virus nucleocapsid protein
US4818527A (en) T cell epitopes of the hepatitis B virus nucleocapsid protein
JP2858848B2 (ja) Ｂ型肝炎ウイルスコア抗原粒子
US5019383A (en) Fatty acid carriers for synthetic peptides
US5589175A (en) Peptides for induction of neutralizing antibodies against human immunodeficiency virus
JP2598245B2 (ja) Ｈｔｌｖ−ｉｉｉ／ｌａｖウイルス関連ペプチドに対する抗体
WO1986005790A1 (en) Immunogenic antigen-carrier protein conjugate for use in a vaccine against malaria
EP0597838B1 (de) Impfstoffzusammensetzungen
US4778784A (en) Cyclic peptide and method of use for inducing an immunological response to hepatitis B virus
CA1280972C (en) Complex immunogen containing synthetic peptides
JPH07116055B2 (ja) 合成ワクチン
Neurath et al. Immunological cross-reactivity between preS2 sequences of the hepatitis B virus envelope proteins corresponding to serological subtypes adw2 and ayw
US4578217A (en) Synthetic antigenic peptide derived from hepatitis B surface antigen
JP2004513897A (ja) 特定交叉反応性を高める抗原構造を得る方法
GB2236754A (en) Peptide fragments of p17 protein of hiv
EP0542753A1 (de) Epitope der prä-s-region des hepatitis-b-virus oberflächenantigens
US4575495A (en) Synthetic antigenic peptide derived from Hepatitis B surface antigen
Ivanov et al. Dituftsin and polytuftsin induce an anti-peptide IgG response to non-immunogenic peptides in mice
EP0171455B1 (de) Synthetisches Peptid, Immunoglobulin und Verfahren zur Immunisierung von Säugetieren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930611

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950701